| OCULUS
INNOVATIVE SCIENCES INTRODUCES NEW 500 ML PACKAGING OF DERMACYN™
WOUND CARE
Formulated with patented Microcyn®
Technology--World’s First Non-Toxic and Stable Super-Oxidized
Water
 SITTARD,
THE NETHERLANDS--(February 23, 2006)— Oculus
Innovative Sciences Netherlands B.V. (www.oculusis.com/europe/index.html)
today announced that the company’s notified body, KEMA,
has granted a CE Mark for the 500 mL configuration of the
company’s Dermacyn™ Wound Care (formulated with
the patented Microcyn® Technology). While previously available
only in a five-liter presentation, both sizes will now be
offered.
Dermacyn™ Wound Care is a super-oxidized
solution intended for use in the debridement, irrigation and
moistening of acute and chronic wounds, ulcers, cuts, abrasions
and burns. Through reducing the microbial load and assisting
in creating a moist environment, it enables the body to perform
its own healing process. Dermacyn™ Wound Care can be
broadly applied within a comprehensive wound treatment.
In October of last year, the company announced
the results of an Italian clinical study that assessed the
safety and performance of Microcyn® Technology in treating
diabetic foot ulcers as compared to povidone iodine (10%)
antiseptic, which is often used as the “standard care”
in treatment of open wounds.
In the study, the Microcyn® Technology
proved superior to the iodine relative to the reduction of
the number of bacterial strains, local adverse effects, surgical
dehiscence (incidence of not healing after surgery due to
infection or ischemia) and healing time.
The company is currently sponsoring several
human clinical studies to assess the safety and performance
of the Microcyn® Technology in treating various wounds
and burns as well as a pre-operative skin preparation.
Information about Dermacyn™
Wound Care
Health Care workers in the European Union can gather more
information about Dermacyn™ Wound Care by phoning +31
(46) 4572 300. The new 500 mL bottle is available immediately.
About Oculus
Oculus Innovative Sciences is a medical technology company
focused on the development, manufacture and marketing of Microcyn®
Technology, which is used to eliminate a wide range of bacteria,
viruses, fungi and spores in a non-toxic manner without creating
resistant strains of pathogens. Microcyn® Technology is
a non-toxic and shelf-stable antimicrobial, which has been
proven effective in safely and quickly killing bacteria (including
antibiotic-resistant strains such as MRSA, Methicillin-Resistant
Staphylococcus; and VRE, Vancomycin-resistant Enterococcus,
in vitro), viruses, spores, and fungi.
Microcyn®-based products are currently
being used in the treatment of both chronic and acute wounds
in the European Union, United States, Mexico and Southeast
Asia. The Microcyn® Technology received CE approval according
to the European Medical Devices Directive (93/42/EEC) for
Dermacyn™ Wound Care in November 2004. It also received
two FDA 510K clearances in May 2005 to be marketed under the
brand name of Dermacyn™ Wound Care in the United States
as a medical device to lubricate, moisten, cleanse and debride
wounds and burns. Statements regarding approved uses only
apply to specified locations and should not be construed as
approvals in other jurisdictions.
Oculus’ principal operations are
in Petaluma, California, and it conducts operations in Europe
and Latin America through its wholly owned subsidiaries, Oculus
Innovative Sciences Netherlands B.V. and Oculus Technologies
of Mexico, S.A. de C.V. Please visit us at www.oculusis.com.
Forward-Looking
Statements
This press release contains forward-looking statements that
involve risks and uncertainties. These forward-looking statements
relate to, among other things, the attributes of our products
and their use in various markets. Our expectations as expressed
in this press release depend upon our ability to develop,
manufacture and supply products that meet defined specifications.
When used in this press release, the words “plan,”
“expect,” “believe,” and similar expressions
generally identify forward-looking statements. These statements
reflect our current expectations. They are subject to a number
of risks and uncertainties, including, but not limited to,
changes in technology and changes in the health sciences market.
In light of the many risks and uncertainties surrounding this
market, you should understand that we cannot assure you that
the forward-looking statements contained in this press release
will be realized.
(Download
PDF: 144 KB)
|
